Researchers interested in the neurobiology of diseases have become increasingly familiar with the notion that mitochondrial defects may be associated not only with classical mitochondrial diseases, such as MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes), but also with a host of adult-onset neurodegenerative disorders, including amyotrophic lateral sclerosis and Parkinson's disease (Schon and Przedborski, 2011) . Similarly, non-cell-autonomous mechanisms have been recognized as key factors underpinning many neurodegenerative disorders (Garden and La Spada, 2012) ; here, the idea is that nonneuronal cells, such as glia, contribute to the demise of neighboring neuronal cells. In this issue of Neuron, Viader et al. (2013) report on the successful collusion between mitochondrial defect and non-cell-autonomous mechanisms in a mouse model of peripheral neuropathy.
The new study further characterized a previously generated mouse model that consists of a selective ablation of the mitochondria transcription factor A gene (Tfam) in Schwann cells (SCs) (Viader et al., 2011) . Because Tfam controls the transcription, replication, and stability of mitochondrial DNA (mtDNA), its ablation in SCs led to the depletion of mtDNA and a failure to express the key components of the electron transport chain, causing a respiration deficiency and an abnormal mitochondrial morphology restricted to SCs (Viader et al., 2011) . Surprisingly, despite these alterations, SC viability was not affected but, instead, a progressive peripheral neuropathy reminiscent of human diabetic neuropathies was observed. This mouse neuropathy was characterized by a preferential loss of small unmyelinated C fibers, followed by that of large myelinated axons and, ultimately, extensive demyelination accompanied by behavioral anomalies (i.e., distal weakness and sensory deficits).
One of the first striking observations in the current study of Viader et al. (2013) is the absence of overt depletion of bioavailable ATP in sciatic nerve extracts (i.e., mixture of mutant SCs and wild-type axons) in pre-or early-pathological Tfam-SC conditional knockout (Tfam-SCKO) mice, even though the authors show that the respiratory chain function is compromised in the mutant sciatic nerves. This apparent paradox may find a resolution in Viader et al. (2013) 's observation that lactate in the mutant nerve extracts is 2-fold higher than controls, most likely because mutant SCs have upregulated their aerobic glycolysis. That lactate, in turn, which is a favored energy source for neurons (Wyss et al., 2011) , should have maintained the axonal integrity. Relevant to this point is the demonstration that in another mouse model of respiratory chain deficiency in SCs and their CNS counterparts, oligodendrocytes, there is a demyelinating neuropathy but, in striking contrast with the study of Viader et al. (2013) , without axonal loss (Fü nfschilling et al., 2012) . Thus, a deficit of Tfam in SCs may be triggering a non-cell-autonomous axonopathy by a mechanism other than energy depletion. Viader et al. (2013) performed an unbiased gene expression profile analysis of sciatic nerves from wild-type and Tfam-SCKO mice, and their attention was drawn to two particular sets of differentially expressed genes. The first one pertained to the integrated stress response (ISR) (Harding et al., 2003) , such as Chop, Mthfd2, and Trib3. Perhaps Viader et al. (2013) thought about ISR as the potential culprit since they knew that a demyelinating neuropathy could result from ISR (Pennuto et al., 2008) . However, in contrast to the latter study, here, the ISR was not linked to either ER stress (e.g., phosphorylation of PKR-like ER kinase or PERK) or the unfolded protein response (e.g., upregulation of BiP/Grp78 or activation of the splicing factor IRE-1). Instead, Viader et al. (2013) provided evidence that the observed ISR is linked to heme-regulated inhibitor kinase (HRI), which, in itself, is a remarkable finding, as HRI had only been shown to be activated by iron deficiency in studies conducted primarily in erythroid cells and never before connected to a mitochondrial defect. Yet, this exciting discovery remains, in the present work, an open-ended story since Viader et al. (2013) do not provide any evidence that HRI actually contributes to the neuropathy of the Tfam-SCKO mice. One can only hope that the role of HRI in mitochondrial neuropathies will be the subject of future studies. Similarly, we may have to wait for further experiments to better understand the nature of molecular pathways linking Tfam deficiency, HRI activation, and ISR response in mediating the observed neuropathy.
The second set of differentially expressed genes, selected by Viader et al. (2013) , was associated with the control of lipid metabolic pathways. For instance, the expression levels of fatty acid synthetase and HMG-CoA reductase (HMGCR) were decreased (in the mutant samples), while the phosphorylation of Acetyl-CoA carboxylase (ACC), which is inhibitory, was increased. Because ACC is known to supply malonyl-CoA for the synthesis of fatty acids, its phosphorylation is predicted to reduce fatty acid synthesis. Similarly, decreased expression of HMGCR is expected to cause a decrease in cholesterol synthesis. Altogether, these features were strongly suggestive of a defect in lipid synthesis in nerve cells in response to SC mitochondrial dysfunction. To explore this idea further, Viader et al. (2013) performed a lipid analysis using state-of-the-art multidimensional shotgun lipidomics. They found in the mutant nerves a deficiency in two subfamilies of glycosphingolipids, cerebrosides and sulfatides, both of which are primarily synthesized by SCs and enriched in peripheral myelin (Chrast et al., 2011) . As Viader et al. (2013) remind us, normal cerebroside and sulfatide content in peripheral myelin is essential for the maintenance of SC-axon contacts and their absence disrupts paranodal junctions, which separate voltage-gated Na(+) and Shaker-type K(+) channels in the node and juxtaparanode, respectively. Consistent with earlier findings, voltage-gated K(+) channel clusters (Kv1.2) were disrupted in the juxtaparanodal axolema, probably causing the 40% reduction in nerve conduction velocity observed in mutant nerves and in agreement with the ultrastructural anomalies showing enlarged nodal gaps. Because these lipid alterations occur before the extensive demyelination and loss of myelin proteins typically found in 4-month-old and older animals, they are probably drivers of the neuropathy in this animal model.
Not content to identify a rather simple lipid-based ''loss-of-function'' mechanism for the demyelination phenotype observed in response to genetically induced mitochondrial dysfunction, Viader et al. (2013) were struck by the 25-fold increase in acylcarnitine in mutant nerves, with a phenomenal increase in long-chain acylcarnitine species (several hundred fold). Importantly, this accumulation of lipids, which is arguably the most fascinating finding reported in this study, is intimately connected to mitochondrial function because acylcarnitines are metabolic intermediates in the transport of fatty acyl groups across mitochondrial membranes as the latter are destined for b-oxidation, supplying a major source of cellular energy (Kompare and Rizzo, 2008) . Together with the gene expression studies, the acylcarnitine phenotype was consistent with a shift from lipid synthesis toward lipid b-oxidation; yet, an aberrant one as the lipid intermediates were not efficiently oxidized, leading to their accumulation. Corroborating this idea, hydroxy-acylcarnitines were also found to accumulate and the NAD + / NADPH ratio was reduced. Importantly, the buildup of acylcarnitines was obvious in younger (i.e., 1-month-old) Tfam-SCKO nerves, suggesting that it may be among the earliest biochemical manifestations. Furthermore, genetic disorders of fatty acid b-oxidation, such as those caused by mutations in long-chain hydroxyacylCoA dehydrogenase or components of the mitochondrial trifunctional protein complex, are associated with enhanced levels of acylcarnitines and juvenile forms of peripheral neuropathies (Kompare and Rizzo, 2008) . The next fundamental question was therefore whether the aberrantly elevated levels of acylcarnitine are toxic to the neighboring axons, particularly in light of previous studies showing that this amphiphilic lipid, which is able to cross lipid bilayers, can perturb the integrity and permeability of cellular membranes (Yamada et al., 2000) . Remarkably, Viader et al. (2013) showed evidence that acylcarnitines not only are released into the culture media by nerve explants, but also are secreted in much larger amounts by mutant SCs lacking Tfam, particularly as long-chain species with 16 or 18 carbons (C16 or C18, respectively), reaching micromolar concentrations in the media within a couple of days. Guided by these findings, Viader et al. (2013) Viader et al. (2013) has significant implications at multiple levels and raises a number of important issues as well. First, by genetically restricting mitochondrial dysfunction to SCs via the cell type-specific ablation of Tfam, the study provides an elegant demonstration that mitochondria can be driving pathological processes relevant to neuropathies of the PNS, both cell-autonomously and non-cell-autonomously. Indeed, an important consequence of the depletion of mtDNA in SCs is a downregulation of some aspects of lipid synthesis, which, in turn, causes deficiencies in specific lipid components of the myelin, such as cerebrosides and sulfatides. These deficiencies, which reflect a cell-autonomous process, are likely to weaken the myelin and may thus contribute to the progressive demyelination observed in Tfam mutant mice, exactly as shown by Fü nfschilling et al. (2012) in their mutant study. In contrast, the identification of acylcarnitines as candidate SC-derived neurotoxic lipids is strongly suggestive of non-cell-autonomous pathogenic mechanisms. While this lipid subfamily has already been linked to genetic diseases involving disorders of lipid b-oxidation and serves as a blood biomarker for these conditions (Kompare and Rizzo, 2008) , this study not only implies that acylcarnitines may be early biomarkers for neuropathies with mitochondrial dysfunction as a causative factor, but it also suggests that it may underlie key aspects of pathogenicity associated with progressive neuropathies. While micromolar concentrations of long-chain acylcarnitine appear to be ''axonotoxic'' in cultured DRGs, a fundamental question is whether its levels found in vivo at sites of intimate contacts between SCs and axons can be sufficiently high to exert toxicity. Further work will be required to demonstrate that this is the case, either by blocking the synthesis of this lipid through genetic or pharmacological means or by identifying reagents, such as antibodies, that can sequester it or diminish its levels. However, the latter may be problematic if acylcarnitines accumulate locally at sites of SC-axon interactions and may not be easily accessible by antibodies. Additional key questions to answer regarding these lipids are how they promote toxicity. Typically, lipids exert their actions either through direct effects on lipid bilayers or via signaling mechanisms involving protein effectors. In the case of acylcarnitines, their soluble amphiphilic nature may endow them with surfactant properties, which could destabilize cellular membranes and lead to changes in permeability, perhaps accounting for the increase in Ca 2+ influx found by Viader et al. (2013) in DRG neurons treated with palmitoylcarnitine. Alternatively, acylcarnitines may interact with membrane proteins, including ion channels, and perturb the permeability of neuronal membranes through these interactions. Whether axons are particularly vulnerable to these lipids is another important question, particularly in light of a growing number of studies indicating that degenerative mechanisms in axons versus somatodendritic compartments may be quite distinct. Finally, in light of Viader et al. (2013) 's findings linking mitochondrial dysfunction to the ISR through the activation of protein kinase HRI, a key question is what is the molecular link between this kinase and machineries controlling lipid synthesis and fatty acid b-oxidation. In this respect, the fact that ISR suppresses the synthesis of both proteins and lipids is particularly intriguing.
Previous reports on dorsal and ventral hippocampal regulation of context learning versus anxiety have been mixed. In this issue of Neuron, a new study by Kheirbek et al. (2013) using optogenetics demonstrates that dentate gyrus granule cell activity in dorsal hippocampus encodes contextual fear learning while ventral granule cell activity regulates anxiety behavior.
The principal role of the hippocampus in the formation of new memories has been the primary focus of neuroscience research for many years, but it has become increasingly clear that this limbic structure also plays a broader role in information processing and behavior. For example, early neurobiological theories considered the hippocampus an integral part of the neural circuitry of emotional experience, and neuroimaging studies demonstrate that hippocampal dysfunction occurs more frequently in psychiatric illnesses such as depression, bipolar, and anxiety disorders. However, the involvement of the hippocampus has also been viewed as ancillary, with no specific role in emotion beyond general inhibitory learning and the consolidation of memory regardless of its emotional content (LeDoux, 2000) .
